These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3679793)

  • 21. I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity.
    Valdés Olmos RA; ten Bokkel Huinink WW; Greve JC; Hoefnagel CA
    Clin Nucl Med; 1992 Mar; 17(3):163-7. PubMed ID: 1611784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing adriamycin-induced early cardiotoxicity by estimating left ventricular ejection fraction using technetium-99m multiple-gated acquisition scan and echocardiography.
    Fatima N; Zaman MU; Hashmi A; Kamal S; Hameed A
    Nucl Med Commun; 2011 May; 32(5):381-5. PubMed ID: 21346663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
    Swain SM; Whaley FS; Ewer MS
    Cancer; 2003 Jun; 97(11):2869-79. PubMed ID: 12767102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
    McKillop JH; Bristow MR; Goris ML; Billingham ME; Bockemuehl K
    Am Heart J; 1983 Nov; 106(5 Pt 1):1048-56. PubMed ID: 6637763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring cardiac function in patients receiving doxorubicin.
    Lu P
    Semin Nucl Med; 2005 Jul; 35(3):197-201. PubMed ID: 16098293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
    Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
    N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in left ventricular diastolic function with doxorubicin therapy.
    Lee BH; Goodenday LS; Muswick GJ; Yasnoff WA; Leighton RF; Skeel RT
    J Am Coll Cardiol; 1987 Jan; 9(1):184-8. PubMed ID: 3794095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
    Lipshultz SE; Colan SD; Gelber RD; Perez-Atayde AR; Sallan SE; Sanders SP
    N Engl J Med; 1991 Mar; 324(12):808-15. PubMed ID: 1997853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential equilibrium gated radionuclide angiocardiography for the detection of doxorubicin cardiotoxicity.
    Pauwels EK; Horning SJ; Goris ML
    Radiother Oncol; 1983 Aug; 1(1):83-7. PubMed ID: 6095370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.
    Shureiqi I; Cantor SB; Lippman SM; Brenner DE; Chernew ME; Fendrick AM
    Br J Cancer; 2002 Jan; 86(2):226-32. PubMed ID: 11870511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Changes in phase analysis without deterioration of the isotopic ejection fraction of the left ventricle in patients treated with adriamycin].
    Buxeda Figuerola M; Candell Riera J; Ortega Alcalde D; Soler Soler J; Doménech Torné F
    Med Clin (Barc); 1988 Apr; 90(15):599-602. PubMed ID: 3398631
    [No Abstract]   [Full Text] [Related]  

  • 33. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation.
    Shapira J; Gotfried M; Lishner M; Ravid M
    Cancer; 1990 Feb; 65(4):870-3. PubMed ID: 2297656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.
    Martin M; Lluch A; Ojeda B; Barnabas A; Colomer R; Massuti B; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-26-S17-30. PubMed ID: 9374088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of cardiotoxicity by radionuclide angiocardiography in the chemotherapy of gynecologic malignancies].
    Yabuta M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1146-56. PubMed ID: 2398300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate.
    Ganz WI; Sridhar KS; Forness TJ
    Am J Clin Oncol; 1993 Apr; 16(2):109-12. PubMed ID: 8452100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity.
    Shuman RD; Ettinger DS; Abeloff MD; Livengood SV; Fortuin NJ
    Johns Hopkins Med J; 1981 Aug; 149(2):57-63. PubMed ID: 7253365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects.
    Bauch M; Ester A; Kimura B; Victorica BE; Kedar A; Phillips MI
    Cancer; 1992 Mar; 69(6):1492-7. PubMed ID: 1531780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin-based chemotherapy: a reassessment.
    Dreicer R; Karwal MW; Midence G; Davis CS; Nettleman M
    Am J Clin Oncol; 1997 Apr; 20(2):132-7. PubMed ID: 9124185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.